Figure 2.

(A) Methylation of LINE1 in the control group (n = 15) and in the treated group (n = 10) (before and after treatment with 25 mg/m² decitabine two times) measured by pyrosequencing. In both cohorts, FF tumour samples and FFPE samples were included. Open symbols and dotted lines represent FF samples, and closed symbols and lines represent FFPE samples. In the treated cohort, two technical replicates per time point were averaged and two biological replicates (two different samples from the same tumour) were used. For patient 6 to patient 10, no biological replicate was available for the pre-treatment sample. For statistical analyses, for pre-treatment and post-treatment samples, the average of all measurements was used. A paired t-test revealed no significant difference in the control cohort (p = 0.9718). For the treated cohort, a significant (p = 0.0075) difference was shown; (B) Methylation of WNT target genes before and after treatment with decitabine in colon cancer patients measured by pyrosequencing (n = 5); (C) Expression of LINE1 and WNT target genes after treatment with decitabine measured by quantitative rt-PCR in fresh-frozen samples (n = 5). Values are the average of two samples (both for pre- and post-treatment samples), except for patient 3, where only one post-treatment sample was available.